Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which showed that Mounjaro ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

As Sky News research revealed thousands of severely obese patients are facing severely delayed treatment, here we look at the ...

Eli Lilly’s blockbuster diabetes drug Mounjaro matched the ability of an older treatment to prevent major heart complications ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

ABC News Medical Correspondent Dr. Darien Sutton take a closer look at the new study by Eli Lilly that their popular diabetes ...

Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...

A woman who lost 23 stone while on Mounjaro has revealed the frustrating side effect she still has to deal with. Weight loss drugs have become extremely popular in the last year or so, with ...

A mum who admitted that she has illegally put her 13-year-old child on Mounjaro weight loss jabs has spoken out on why she ...